YUH-JYH JONG
CHAIR Professor YUH-JYH JONG
|
Education
|
|
Doctor of Medicine: Kaohsiung Medical College, Taiwan
Master of Medicine: Kaohsiung Medical College, Taiwan
D. M. Sci.: Tokyo Women’s Medical University, Japan
|
|
Current Position
|
|
Chair Professor, Kaohsiung Medical University (KMU)
Chair Professor, National Yang Ming Chiao Tung University
Visiting Staff, Departments of Pediatrics and Laboratory Medicine, KMU Hospital
Honorary Director, Taiwan Child Neurology Society
Director, Taiwan Human Genetics Society
Executive Director, Formosan Medical Association
Executive Director, Taiwan SMA Families
|
|
Experience
|
|
(1) President, KMU (2018/8-2021/8)
(2) Professor & Dean, College of Biological Science and Technology, National Chiao Tung University (NCTU) (2013/8-2018/8)
(3) Senior University Counselor, NCTU (2012/8-2013/7)
(4) Vice President, KMU (2006/7-2012/6)
(5) Professor, Graduate Institute of Clinical Medicine, College of Medicine, KMU (2015/8-present)
(6) Professor, Graduate Institute of Medicine, College of Medicine, KMU (2005/8-2015/7)
(7) Chair, Graduate Institute of Medicine, College of Medicine, KMU (2004/8-2006/7)
(8) Vice Superintendent, KMU Hospital; Chair, Departments of Pediatrics/Clinical Research, KMU Hospital; Director, Departments of Pediatrics and Medical Genetics, College of Medicine, KMU (2003/8-2006/7)
(9) Superintendent, KMU Hsiao-Kang Hospital; Director, Department of Laboratory Medicine, KMU Hsiao-Kang Hospital (2003/8-2006/7)
(10) Professor, Departments of Pediatrics/ Laboratory Medicine, College of Medicine, KMU (2000/8-2005/7)
|
|
Awards
|
|
1998 Kaohsiung Medical College Education Reform Contribution Award
2004 Led Hsiao-Kang Hospital to be recognized by the Department of Health of the Executive Yuan as a Medical Institution with Meritorious Service in the Prevention and Treatment of SARS
2005 The 3rd National Golden Palm Tree Award
2011 Taiwan Pediatric Education Contribution Award
2013 Taiwan Pediatric Association Award
2020 Taiwan Child Neurology Society Contribution Award
2021 Taiwan Medical Association Taiwan Medical Model Award
|
|
Specialty and Research Field
|
|
Pediatrics, Pediatric NeurologyNeuromuscular Diseases, Translational Medicine, Precision Medicine
|
|
Representative Publications
|
|
1. Chen TH, Chang SH, Wu YF, Yen YP, Hsu FY, Chen YC, Ming Y, Hsu HC, Su YC, Wong ST, Hung JH, Chiou SH, Jong YJ*, Chen JA*. MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice. Mol Ther Nucleic Acids 2023;32:144-60.
2. Crawford TO*, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z; NURTURE Study Group. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 2023 ;68(2):157-70.
3. Chou SH, Lin SY, Wu MH, Tien YC, Jong YJ, Liang WC, Lu YM, Shih CL, Lu CC*. Intravenous tranexamic acid reduces blood loss and transfusion volume in scoliosis surgery for spinal muscular atrophy: results of a 20-year retrospective analysis. Int J Environ Res Public Health 2021;18(19):9959.
4. Sophelia Chan HS, Chae JH, Chien YH, Ko TS, Lee JH, Lee YJ, Nam SO, Jong YJ* Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. J Neurol Neurosurg Psychiatry 2021;92(11):1244-6.
5. Ou SF, Ho CS, Lee WT, Lin KL, Cynthia C Jones, Jong YJ*, SMA Study Group. Natural history in spinal muscular atrophy type I in Taiwanese population: A longitudinal study. Brain Dev 2021;43(1):127-34.
6. Liang WC, Jong YJ*, Wang CH, Wang CH, Tian X, Chen WZ, Kan TM, Narihiro Minami, Ichizo Nishino, C Wong LJ. Clinical, pathological, imaging, and genetic characterization in a Taiwanese cohort with limb-girdle muscular dystrophy. Orphanet J Rare Dis 2020;15(1):160.
7. Shen PC, Lu CC, Liang WC, Tien YC, Jong YJ, Lu YM, Liu ZM, Shih CL, Chou SH*. Predictors for Deformity Progression in a Spinal Muscular Atrophy Cohort After Scoliosis Correction Surgery. Clin Spine Surg. 2020;33(8):E407-14.
8. De Vivo DC*, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Staropoli JF, Kerr D, Sandrock AW, Stebbins C, Petrillo M, Braley G, Johnson K, Foster R, Gheuens S, Bhan I, Reyna SP, Fradette S, Farwell W, NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019;29(11):842-56.
9. Chen TH, Liang WC, Chen IC, Liu YC, Hsu JH, Jong YJ*. Combined noninvasive ventilation and mechanical insufflator–exsufflator for acute respiratory failure in patients with neuromuscular disease: effectiveness and outcome predictors. Ther Adv Respir Dis 2019;13:1753466619875928.
10. Wang CC, Chen CA*, Jong YJ, Kou HS. Specific gene capture combined with restriction-fragment release for directly fluorescent genotyping of single-nucleotide polymorphisms in diagnosing spinal muscular atrophy. Anal Chem 2018;90(19):11599-606.
11. Finkel RS*, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377(18):1723-32.
12. Victor RG*, Sweeney HL, Finkel R, McDonald CM, Byrne B, Eagle M, Goemans N, Vandenborne K, Dubrovsky AL, Topaloglu H, Miceli MC, Furlong P, Landry J, Elashoff R, Cox D, Tadalafil DMD Study Group. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology 2017;89(17):1811-20.
13. Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS, Lee WT, Jong YJ, Ko TM, Hwu WL*. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr 2017;190:124-9.
14. Lin TL, Chen TH, Hsu YY, Cheng YH, Juang BT, Jong YJ*. Selective neuromuscular denervation in Taiwanese severe spinal muscular atrophy mouse can be reversed by morpholino antisense oligonucleotides. PLoS One 2016;11(4):e0154723.
15. Tian X, Liang WC, Feng Y, Wang J, Zhang VW, Chou CH, Huang HD, Lam CW, Hsu YY, Lin TS, Chen WT, Wong LJ*, Jong YJ*. Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. Neurol Genet 2015;1(2):e14.
16. Chen TH, Hsu JH, Wu JR, Dai ZK, Chen IC, Liang WC, Yang SN, Jong YJ*. Combined noninvasive ventilation and mechanical in-exsufflator in the treatment of pediatric acute neuromuscular respiratory failure. Pediatric Pulmonol 2014;49(6):589-96.
17. Liang WC, Hayashi YK, Ogawa M, Wang CH, Huang WT, Nishino I, Jong YJ*. Limb-girdle muscular dystrophy type 2I is not rare in Taiwan. Neuromuscu Disord 2013;23(8):675-81.
18. Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK, Nishino I, Lin CW, Shih HH, Huang CC, Liang WC, Wang WF, Jong YJ*. Infantile facioscapulohumeral muscular dystrophy revisted: Expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 2013;23(4):298-305.
19. Hsu YY, Jong YJ, Tsai HH, Tseng YT, An LM, Lo YC*. Triptolide increases SMN transcript and protein levels in human SMA fibroblasts and improves survival in SMA-like mice. Br J Pharmacol 2012;166(3):1114-26.
20. Chen YS, Shih HH, Chen TH, Kuo CH, Jong YJ*. Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III. J Pediatr 2012;160(3):447-51.
21. Chen TH, Chang JG, Yang YH, Mai HH, Liang WC, Wu YG, Wang HY, Huang YB, Wu SM, Chen YC, Yang SN, Jong YJ*. A randomized, double-blind, placebo-controlled trial of hydroxyrea in spinal muscular atrophy. Neurology 2010;75(24):2190-7.
22. Liang WC, Ohkuma A, Hayashi YK, López LC, Hirano M, Nonaka I, Noguchi S, Chen LH, Jong YJ*, Nishino I*. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl CoA dehydrogenase deficiency. Neuromusc Disord 2009;19(3):212-6.
23. Liang WC, Yuo CY, Liu CY, Lee CS, Goto K, Hayashi YK, Jong YJ*. Novel LMNA mutation in a Taiwanese family with autosomal dominant Emery-Dreifuss muscular dystrophy. J Formos Med Assoc 2007;106(2 Suppl):S27-31.
24. Chang HC, Hung WC, Chuang YJ, Jong YJ*. Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int 2004;45(7):1107-12.
25. Chang JG*, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98(17):9808-13.
26. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H*. A mouse model for spinal muscular atrophy. Nature Genet 2000;24(1):66-70.
27. Jong YJ*, Chang JG, Lin SP, Yang TY, Wang JC, Chang CP, Lee CC, Li H, Hsieh-Li HM, Tsai CH. Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients. J Neurol Sci 2000;173(2):147-53.
28. Jong YJ*, Chang JG, Wu JR. Large-scale deletions in a Chinese infant associated with a variant form of Werdnig-Hoffmann disease. Neurology 1998;51(3):878-9.
29. Chang JG*, Jong YJ, Huang JM, Wang WS, Yang TY, Chang CP, Chen YJ, and Lin SP: Molecular basis of spinal muscular atrophy in Chinese. Am J Hum Genet 1995;57(6):1503-05.
30. Liu GC*, Jong YJ, Chiang CH, Jaw TS. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993;186(2):475-80.
31. Liu GC*, Jong YJ, Chiang CH, Yang CW. Spinal muscular atrophy: MR evaluation. Pediatr Radiol 1992;22(8):584-6.
32. Jong YJ*. Chuang YH, Chen SS, Chen BH, Chiang CH. Dystrophin immunostaining of muscle from Chinese patients with various neuromuscular diseases. J Formos Med Assoc 1991;90(12):1143-8.
|
MEI-REN PAN
MEI-REN PAN
|
Education
|
|
PhD, Graduate Institute of Medicine, Kaohsiung Medical University, Taiwan
|
|
◎專長領域◎
|
|
Cancer cell metastasis; lymphatic angiogenesis; cancer cell drug resistance mechanism; gene mutation repair mechanism
|
|
Intramural Experience
|
|
MD Anderson Cancer Ctr., Houston, TX 博士後研究員 (2008-2011)
國家衛生研究院癌症研究所博士後研究員 (2011-2013)
高雄醫學大學臨床醫學研究所助理教授（2013~2018.01）
高雄醫學大學臨床醫學研究所副教授（2018.02~2021.01）
高雄醫學大學臨床醫學研究所教授（2021.02~）
高雄醫學大學附設中和紀念醫院臨床醫學研究部癌症研究室主任（2021.08~)
|
|
Research Publish
|
|
(Selected)
1. Ou-Yang F, Li CL, Chen CC, Shen YC, Moi SH, Luo CW, Xia W, Wang YN, Lee HH, Wang LH, Wang SC*, Pan MR*, Hou MF*, Hung MC*. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. American Journal of Cancer Research. 2022;12(1):123-137.
2. Kao CN, Moi SH, Hou MF, Luo CW, Chen FM, Pan MR.RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. Journal of personalized medicine. 2021 Jul 13;11(7):655.
3. Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nature communications. 2021 May 13;12(1):2788.
4. Wang HC, Chan LP, Wu CC, Chang SJ, Moi SH, Luo CW, Pan MR. Silencing DNA Polymerase β Induces Aneuploidy as a Biomarker of Poor Prognosis in Oral Squamous Cell Cancer. International Journal of Molecular Sciences. 2021 Feb 27;22(5):2402. doi: 10.3390/ijms22052402.
5. Wang HC, Chou MC, Wu CC, Chan LP, Moi SH, Pan MR*, Liu TC*, Yang CH*. Application of the Interaction between Tissue Immunohistochemistry Staining and Clinicopathological Factors for Evaluating the Risk of Oral Cancer Progression by Hierarchical Clustering Analysis: A Case-Control Study in a Taiwanese Population.Diagnostics (Basel). 2021 May 21;11(6):925.
6. Huang WL, Luo CW, Chou CL, Yang CC, Chen TJ, Li CF, Pan MR. High Expression of UBE2B as a Poor Prognosis Factor in Patients With Rectal Cancer Following Chemoradiotherapy. Anticancer Research. 2020 Nov;40(11):6305-6317. doi: 10.21873/anticanres.
7. Luo CW, Hou MF, Huang CW, Wu CC, Ou-Yang F, Li QL, Wu CC and Pan MR. The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. American Journal of Cancer Research. 2020 Dec 1;10(12):4325-4341.
8. Hsu YC, Luo CW, Huang WL, Wu CC, Chou CL, Chen CI, Chang SJ, Chai CY, Wang HC, Chen TY, Li CF, Pan MR. BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Radiother Oncol. 2020 Aug;149:249-258. doi: 10.1016/j.radonc.2020.06.023.
9. Pan MR, Wu CC, Kan JY, Li QL, Chang SJ, Wu CC, Li CL, Ou-Yang F, Hou MF, Yip HK, Luo CW. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers (Basel). 2019 Dec 30;12(1):94. doi: 10.3390/cancers12010094.
10. Tsai HL, Pang SY, Wang HC, Luo CW, Li QL, Chen TY, Fang SY, Wang JY, Pan MR. Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer. American Journal ofCancer Research. 2019 Nov; 1;9(11): 2544-2553.
11. Wang HC, Chou CL, Yang CC, Huang WL, Hsu YC, Luo CW, Chen TJ, Li CF, Pan MR. Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy. International Journal of Molecular Sciences. 2019 Aug 21;20(17).pii: E4087. doi: 10.3390/ijms20174087.
12. Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine. 2019 Jun 24;8(6). pii:E903. doi: 10.3390/jcm8060903. Review.
13. Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW*. FAK is required for tumor metastasis-related fluid microenvironment in triple-negative breast cancer. JournalofClinicalMedicine. 2019Jan2;8(1). pii:E38.doi: 10.3390/jcm8010038.
14.
Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences. 2018 Nov 13;19(11). pii: E3584. doi: 10.3390/ijms19113584. Review.1.
15. Tian YF, Wang HC, Luo CW, Hung WC, Lin YH, Chen TY, Li CF, Lin CY, Pan MR. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. American Journal of Cancer Research. 2018 Sep 1;8(9):1812-1822.
16. Luo CW, Hsiao IL, Wang JY, Wu CC, Hung WC, Lin YH, Chen TY, Hsu YC, Cheng TL, Pan MR. Cell Motility Facilitated by Mono(2-ethylhexyl) Phthalate via Activation of the AKT-β-Catenin-IL-8 Axis in Colorectal Cancer. Journal of Agricultural and Food Chemistry. 2018Sep 19;66 (37) :9635-9644.
17. Luo CW, Wu CC, Chang SJ, Chang TM, Chen TY, Chai CY, Chang CL, Hou MF, Pan MR. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.Experimental CellResearch. 2018 Feb 1;363(1):65-72.
18. Pan MR, Hsu MC, Chen LT, Hung WC. Orchestration of H3K27 methylation: mechanisms and therapeutic implication. CellularandMolecularLifeSciences. 2018Jan;75(2):209-223.
19. Hou MF, Luo CW, Chang TM, Hung WC, Chen TY, Tsai YL, Chai CY, Pan MR. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer. ExperimentalCell Research. 2017 Oct 15;359(2):458-465.
20. Luo CW, Wang JY, Hung WC, Peng Guang, Tsai YL, Chang TM, Chai CY, Lin CH and Pan MR. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiotherapy and Oncology. 2017 Sep;124(3):395-402.
21. Yin HL,Wu CC, Lin CH, Chai CY, Hou MF, Chang SJ, Tsai HP, Hung WC, Pan MR* and Luo CW*. Beta1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. InternationalJournal ofMolecular Sciences2016 Aug31;17(9). pii:E1432.
22. Pan MR, Hsu MC, Chen LT, Shen YS, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget 2016 Sep 20;7(38):61136-61151.
23. Pan MR, Li Kaiyi, Lin SY and Hung WC. Connecting the Dots: From DNA Damage and Repair to Aging. International Journal of Molecular Sciences. 2016 May 6;17(5).
24. Pan MR, Hsu MC, Liu JY, Chen LT, Hung WC. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation. Scientific Reports. 2015 Dec 21;5:18709.
25. Leu MH*, Huang CC*, Pan MR*, Chen HH, Hung WC. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clinical Cancer Research. 2012; 18(23): 6416-25.
26. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Research. 2012; 72(11): 2802-13.
27. Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor Treatment. The Journal of Biological Chemistry. 2012; 287 (9): 6764-72.
28. Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX regulates DNA damage response signaling. The Journal of Biological Chemistry. 2011; 286(32): 28599-607.
|
Shu-Pin Huang
|
Personal Data:
Name: Shu-Pin Huang M.D.& Ph.D.
Address: Department of Urology,
Kaohsiung Medical University
No. 100, Shih-Chuan 1st Road , Kaohsiung, TAIWAN 807
Marital Status: Married
Birth Year: 1972
Place of Birth: Kaohsiung, Taiwan
|
|
Current Position: Professor and Visiting Staff
Department of Urology, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, TAIWAN 807
Phone: 886-7-3121101 ext. 6694
Fax: 886-7-3211033
E-mail: shpihu73@gmail.com; shpihu@yahoo.com.tw
Education:
1. School of Medicine, Kaohsiung Medical University (KMU), 1990-1997 (M.D. Degree)
2. Graduate Institute of Medicine, Kaohsiung Medical University (KMU) 1999~2004 (Ph.D. Degree)
Post-Graduate Training:
1. Resident , Dept. of Urology, KMU 1997-1999
2. Chief Resident, Dept. of Urology, KMU, 2000
3. Visiting Staff, Dept. of Urology, KMU, 2000 ~ present
Postdoctoral Research
George Whipple Lab for Cancer Research, University of Rochester Medical Center, NY, USA, 2005~2006
Professional Society Membership:
1. Member of Taiwan Urological Association (TUA)
2. Member of American Urological Association (AUA)
3. Member of European Association of Urology (EAU)
4. Member of Urological Association of Asia (UAA)
Role of PI in Clinical Trials:
|
Protocol Name and Number: Role: PI
|
Study Period
|
|
Protocol number.: 212082PCR3001
An Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy.
|
2012.09.01~2014.12.31
|
|
Protocol Number: MDV3100-14
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
|
2013.11.01~2018.11.01
|
|
Protocol Number: ARI 114265
A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin(0.2mg) with tamsulosin(0.2mg) monotherapy, administered once daily for 2years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia.
|
2014.01.01~2017.12.31
|
|
Protocol Number: 9785-CL-0232
Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
|
2014.05.01~2017.03.31
|
|
Protocol Number: 9785-CL-0403
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD)
|
2014-7-30~2018-06-30
|
|
Protocol Number: ONC-MA-1001
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis
|
2015~
|
|
Protocol Number: Orion Pharma Protocol: 3104007
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High- Risk Non-Metastatic Castration-Resistant Prostate Cancer
|
2015~
|
|
Protocol Number: MDV3100-13
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
|
2016~
|
|
Bayer ARASENS 17777 study
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
|
2017~
|
|
Protocol Number: MVT-601-3201
HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
|
2017~
|
|
Protocol Number: 9785-CL-0335
ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
|
2017~
|
|
Protocol Number: CO39303
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
|
2017~ 2018
|
Biography;
Prof/Dr. Shu-Pin Huang has received his PhD in Graduate of Medicine, Kaohsiung Medical University during the period of 1999 to 2004. Currently, he is working as Professor and Visiting Staff in Department of Urology, Kaohsiung Medical University Hospital & Kaohsiung Medical University in Taiwan. He is serving as a reviewer of several reputed journals like New England Journal of Medicine, Clinical Cancer Research, PLOS One, Cancer, Clinica Chimic Acta, Annals of Surgical Oncology, Journal of Endourology, International Journal of Oncology, Medicine, J Endourology, … etc. Prof Huang has published over 140 research articles in peer-review SCI journals. He is a member of Urological Association of Taiwan, American Urological Association (AUA) and European Association of Urology (EAU) and also served as Academic Editor for Medicine and Member of Editorial Board of International Journal of Urology. In additional to general Urology, Renal Transplantation and Robotic Surgery in Urology Oncology (majority on radical prostatectomy and Uro-oncology), Dr. Huang’s research interests were mainly focus on: Prostate Cancer, Molecular Epidemiology, Pharmacogenomic studies, Metabolic syndrome, Endocrine-Related Cancer, Urolithiasis, Andrology, Male Erectile dysfunction … etc.
Selected Published Papers:
1. Huang CH, Wang SC, Chen IC, Chen YT, Liu PL, Fang SH, Huang SP, Yeh HC, Liu CC, Lee PY, Lin TC, Cheng WC, Su CC, Wu HE, Chen YR, Li CY. (2021, Jun). Protective Effect of Piplartine against LPS-Induced Sepsis through Attenuating the MAPKs/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. Pharmaceuticals (Basel), Jun 18;14(6):588. .
2. Huang SP, Chen LC, Chen YT, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, Jun). PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer. Cancer Genomics Proteomics., 18(3):325-334.. 本人為第一作者.
3. Tsai YC, Huang CY, Hsueh YM, Fan YC, Fong YC, Huang SP, Geng JH, Chen LC, Lu TL, Bao BY. (2021, Jun). Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes. Life sciences, 275:119396.
4. Huang SP, Chen YT, Chen LC, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, May). NRG1 Genetic Variant Influences the Efficacy of Androgen- Deprivation Therapy in Men with Prostate Cancer. Biomedicines, 9(5):528. 本人為第一作者.
5. Su CC, Wang SC, Chen IC, Chiu FY, Liu PL, Huang CH, Huang KH, Fang SH, Cheng WC, Huang SP, Yeh HC, Liu CC, Lee PY, Huang MY, Li CY. (2021, May). Zerumbone Suppresses the LPS-Induced Inflammatory Response and Represses Activation of the NLRP3 Inflammasome in Macrophages. Front Pharmacol. , 12:652860.
6. Wang SH, Huang SP, Pan YJ, Hsiao PC, Li CY, Chen LC, Yu CC, Huang CY, Lin VC, Lu TL, Bao BY. (2021, May). Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer. Am J Cancer Res, 11(5):2331-2342.
7. Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. (2021, Feb). Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks. Frontiers in Immunology, Feb 3;11:610492.. 本人為通訊作者.
8. Liu CC, Huang SP, Hsieh TJ, Lee CH, Cheng KH, Huang TY, Geng JH, Li CC, Wu WJ, Lee YC. (2021, Feb). Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. Andrology, 9(3):863-872. .
9. Huang CY, Huang SP, Hsueh YM, Chen LC, Lu TL, Bao BY. (2020, Nov). Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. Cancer Genomics Proteomics., 17(6):827-833..
10. Li CC, Chien TM, Huang SP, Yeh HC, Lee HY, Ke HL, Wen SC, Chang WC, Juan YS, Chou YH, Wu WJ. (2020, Nov). Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors. J Clin Med., 9(11):3658..
11. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators (2020, Sep). Nonmetastatic, Castration- Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med, 383(11):1040-1049..
12. Liu CC, Hsieh TJ, Wu CF, Lee CH, Tsai YC, Huang TY, Wen SC, Lee CH, Chien TM, Lee YC, Huang SP, Li CC, Chou YH, Wu WJ, Wu MT. (2020, Sep). Interrelationship of environmental melamine exposure, biomarkers of oxidative stress and early kidney injury. J Hazard Mater., 396:122726.
13. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. (2020, Jun). Oral Relugolix for Androgen- Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. , 382(23):2187-2196.
14. Ke CC, Chen LC, Yu CC, Cheng WC, Huang CY, Lin VC, Lu TL, Huang SP, Bao BY. (2020, May). Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers (Basel)., ; 12(5):1346 . 本人為通訊作者.
15. Yu CC, Chen LC, Huang CY, Lin VC, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Apr). Genetic association analysis identifies a role for ANO5 in prostate cancer progression. Cancer Med., 9(7):2372-2378. 本人為通訊作者.
16. Yu CC, Chen LC, Lin WH, Lin VC, Huang CY, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Mar). Genetic Association Analysis of Cell Cycle Regulators Reveals YWHAZ Has Prognostic Significance in Prostate Cancer. Cancer Genomics Proteomics. , 17(2):209-216. 本人為通訊作者.
17. Lee CH, Chen LC, Yu CC, Lin WH, Lin VC, Huang CY, Lu TL, Huang SP, Bao BY. (2019, Nov). Prognostic Value of CD1B in Localised Prostate Cancer.. International Journal of Environment Research and Public Health, 16(23). pii: E4723. 本人為通訊作者.
18. Yu CC, Chen LC, Lin VC, Huang CY, Cheng WC, Hsieh AR, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Jun). Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.. Cancer Medicine, 8(6): 2777–2783. 本人為通訊作者.
19. Su CC, Hsieh KL, Liu PL, Yeh HC, Huang SP, Fang SH, Cheng WC, Huang KH, Chiu FY, Lin IL, Huang MY, Li CY (2019, Apr). AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.. International Journal of Molecular Sciences, 20(7): 1647.
20. Yu CC, Chen LC, Chiou CY, Chang YJ, Lin VC, Huang CY, Lin IL, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Apr). Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression. Cancer Cell International, 19: 87. 本人為通訊作者.
21. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR1; ARAMIS Investigators. (2019, Mar). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.. The New England Journal of Medicine, 380(13):1235-1246..
22. Huang CY, Hsueh YM, Chen LC, Cheng WC, Yu CC, Chen WJ, Lu TL, Lan KJ, Lee CH, Huang SP, Bao BY (2018, Nov). Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival. Cancer Medicine, 7(12): 6104–6111. 本人為通訊作者.
23. Liu CC, Lee YC, Huang SP, Cheng KH, Hsieh TJ, Huang TY, Lee CH, Geng JH, Li CC, Wu WJ. (2018, Nov). Hepatocyte Nuclear Factor-4α P2 Promoter Variants Are Associated With the Risk of Metabolic Syndrome and Testosterone Deficiency in Aging Taiwanese Men.. Journal of Sexual Medicine, 15(11): 1527- 1536.
24. Chen YC, Chen HW, Lee CH, Huang SP. (2018, Oct). A Rare Delayed Bladder Migration of a Hem-o-lok Clip 5 Years after Robotic-Assisted Radical Prostatectomy.. Urologia Internationalis, 19:1-3. 本人為通訊作者.
25. Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, Tsai KK. (2018, Sep). ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene, 38(8):1340-1353.
26. Chen YC, Chen HW, Huang SP, Yeh HC, Li CC. (2018, Aug). Adequate rectal preparation reduces hospital admission for urosepsis after transrectal ultrasound - guided prostate biopsy.. International Braz J Urol , 5;44.
27. Huang EY, Chang YJ, Huang SP, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Bao BY. (2018, Jul). A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer. Journal of Cellular and Molecular medicine, 22(7); 3661-3670. 本人為第一作者.
28. Liu CC, Hsieh TJ, Wu CF, Tsai YC, Huang SP, Lee YC, Huang TY, Shen JT, Chou YH, Huang CN, Wu WJ, Wu MT. (2017, Dec). Urinary melamine excretion and increased markers of renal tubular injury in patients with calcium urolithiasis: A cross-sectional study.. Environmental Pollution, 231(Pt 2):1284- 1290.
29. Cha TL, Wu TT, Vogelzang NJ, Huang CY, Huang SP, Lin CC, Ou YC, Pang ST, Shen DH, Wu WJ, Chang WY. (2017, Nov). Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. Journal of the Formosan Medical Association, 116(11):825-836.
30. Lin VC, Huang SP, Huang CY, Yu CC, Yin HL, Huang TY, Lee CH, Lu TL, Bao BY. (2017, Sep). Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.. International Journal of Medical Sciences, 14(12):1301-1306.
31. Lin YC, Hour TC, Tsai YC, Huang SP, Wu WJ, Chen CH, Pu YS, Chung SD, Huang CY. (2017, Sep). Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan population.. Urologic Oncology, 35(9):543.e7- 543.e16.
32. Liu CC, Huang SP, Cheng KH, Hsieh TJ, Huang CN, Wang CJ, Yeh HC, Tsai CC, Bao BY, Wu WJ, Lee YC. (2017, Jun). Lower SHBG level is associated with higher leptin and lower adiponectin levels as well as metabolic syndrome, independent of testosterone.. Scientific Reports, 35(9):543.e7-543.e16.
33. Lin VC, Huang SP, Ting HJ, Ma WL, Yu CC, Huang CY, Yin HL, Huang TY, Lee CH, Chang TY, Lu TL, Bao BY. (2017, May). Vitamin D receptor-binding site variants affect prostate cancer progression.. Oncotarget, 8(43):74119-74128.
34. Lee YC, Huang SP, Tsai CC, Cheng KH, Juan YS, Wu WJ, Bao BY, Huang CN, Wang CJ, Liu CC. (2017, Apr). Associations of VEGF Gene Polymorphisms With Erectile Dysfunction and Related Risk Factors.. Journal of Sexual Medicine, 14(4):510-517.
35. Geng JH, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Huang SP, Bao BY. (2016, Nov). Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.. International Journal of Molecular Sciences , 17(12):1970. 本人為通訊作者.
36. Lin VC, Lu TL, Yin HL, Yang SF, Lee YC, Liu CC, Huang CY, Yu CC, Chang TY, Huang SP, Bao BY. (2016, Nov). Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer. International Journal of Molecular Sciences, 17(12):1996. . 本人為通訊作者.
37. Lee YC, Huang SP, Juan YS, Huang TY, Liu CC. (2016, Sep). Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males.. The Aging Male, 19(3):197-201.
38. Chien TM, Lu YM, Geng JH, Huang TY, Ke HL, Huang CN, Li CC, Chou YH, Wu WJ, Huang SP. (2016, Aug). Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients. Asian Pacific Journal of Cancer Prevention, , 17(3):1187-91. 本人為通訊作者.
39. Lee CH, Pao JB, Lu TL, Lee HZ, Lee YC, Liu CC, Huang CY, Lin VC, Yu CC, Yin HL, Huang SP, Bao BY. (2016, Aug). Prognostic Value of Prostaglandin- endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy. International Journal of Medical Sciences, 13(9):696- 700. 本人為通訊作者.
40. Lee YC, Juan YS, Liu CC, Bao BY, Wang CJ, Wu WJ, Huang CN, Huang SP. (2016, Aug). The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. BJU International, 118(2):313-9.. 本人為通訊作者.
41. Yeh HC, Chien TM, Wu WJ, Li CC, Li WM, Ke HL, Chou YH, Wang CJ, Huang SP, Li CF, Liang PI, Huang CN. (2016, Aug). Is preoperative anemia a risk factor for upper tract urothelial carcinoma following radical nephroureterectomy? Urologic Oncology.34(8):337.e1-9.
42. Tai SY, Huang SP, Bao BY, Wu MT. (2016, Jul). Urinary melatonin- sulfate/cortisol ratio and the presence of prostate cancer: A case-control study.. Scientific Reports, 6:29606.
43. Tai SY, Hsieh HM, Huang SP, Wu MT. (2016, Mar). Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies. BMC Cancer. 16:242.本人為通訊作者.
44. Bao BY, Lin VC, Yu CC, Yin HL, Chang TY, Lu TL, Lee HZ, Pao JB, Huang CY, Huang SP. (2016, Feb). Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival.. Scientific Reports. 6:22124. 本人為通訊作者.
45. Yang SM, Huang CY, Shiue HS, Huang SP, Pu YS, Chen WJ, Lin YC, Hsueh YM. (2015, Dec). Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma.. PLOS ONE, 10(12):e0145410.
46. Geng JH, Huang SP, Huang CY. (2015, Oct). Prognostic factors in Taiwanese patients with penile-invasive squamous cell carcinoma.. Kaohsiung Journal of Medical Sciences , 31(10):523-8..
47. Yeh HC, Jan HC, Wu WJ, Li CC, Li WM, Ke HL, Huang SP, Liu CC, Lee YC, Yang SF, Liang PI, Huang CN. (2015, Oct). Concurrent Preoperative Presence of Hydronephrosis and Flank Pain Independently Predicts Worse Outcome of Upper Tract Urothelial Carcinoma.. PLOS ONE, 10(10):e0139624.
48. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Lu TL, Chiang HC, Bao BY. (2015, Sep). Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer.. Scientific Reports, 5:14045.
49. Liu CC, Hsieh HM, Wu CF, Hsieh TJ, Huang SP, Chou YH, Huang CN, Wu WJ, Wu MT. (2015, Apr). Long-term prescription of α-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention-a nationwide population- based study. PLOS One, 10(4):e0122494.
50. Chen CS, Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Bao BY. (2015, Feb). Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.. Int J Med Sci., 12(3):243-7.
51. Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Juang SH, Bao BY. (2015, Feb). Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer. Scientific Reports. 5:8556.
52. Cheng KH, Hsi E, Liu CC, Huang CN, Lee YC, Chu CS, Bao BY, Chang CF, Huang SP, Kuo PL, Lai WT. (2015, Jan). The Associations of Novel Vitamin D3 Metabolic Gene CYP27A1 Polymorphism, Adiponectin/Leptin Ratio, and Metabolic Syndrome in Middle-Aged Taiwanese Males. International Journal of Endocrinology, 2015:658151.
53. Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. (2014, Dec). Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer, 135(11):2661-7. NSC 100-2314-B-039-009-MY3. 本人為第一作者.
54. Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Lee YC, Yang KF, Lee MH, Huang SP. (2014, Aug). Clinical predictor of survival following docetaxel-based chemotherapy. Oncol Lett. , 8(4):1788-1792. 本人為通訊作者.
55. Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS. (2014, Jun). EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol, 89(4):591-605.
56. Huang TY, Lin JP, Huang SP. (2014, Apr). Medullary sponge kidney on retrograde pyelography. Chonnam Med J., 50(1):21-2. 本人為通訊作者.
57. Lin VC1, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY. (2014, Apr). Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients. Arch Toxicol., 88(4):901-11. NSC 100- 2314-B-039-009-MY3. 本人為通訊作者.
58. Yu CC, Lin VC, Huang CY, Liu CC, Wang JS, Wu TT, Pu YS, Huang CH, Huang CN, Huang SP*, Bao BY*. (2013, Dec). Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Ann Surg Oncol. , 20 Suppl 3:492-9. 本人為通訊作者.
59. Huang SP, Lin VC, Lee YC, Yu CC, Huang CY, Chang TY, Lee HZ, Juang SH, Lu TL, Bao BY. (2013, Nov). Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients. . Eur J Cancer., 49(17):3729-37.NSC 99-2314-B-037-018-MY3. 本人為第一作者.
60. Huang TY1, Lin JP, Lieu AS, Chen YT, Chen HS, Jang MY, Shen JT, Wu WJ, Huang SP, Juan YS. (2013, Oct). Pituitary apoplexy induced by Gonadotropin- releasing hormone agonists for treating prostate cancer-report of first Asian case. World J Surg Oncol., 11:254.
61. Cheng KH, Huang SP, Huang CN, Lee YC, Chu CS, Chang CF, Lai WT, Liu CC. (2013, Mar). The impact of estradiol and 1,25(OH)2D3 on metabolic syndrome in middle-aged Taiwanese males. PLoS One., 8(3):e60295.
62. Chang CF, Pao JB, Yu CC, Huang CY, Huang SP, Yang YP, Huang CN, Chang TY, You BJ, Lee HZ, Hour TC, Bao BY. (2013, Feb). Common Variants in IGF1 Pathway Genes and Clinical Outcomes After Radical Prostatectomy. Ann Surg Oncol., 20(7):2446-52.
63. Yu CC, Huang SP, Lee YC, Huang CY, Liu CC, Hour TC, Huang CN, You BJ, Chang TY, Huang CH, Bao BY. (2013, Jan). Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One., 8(1):e54627.
